Nature 551 , 100104 (2017)
FDA Crackdown on Compounded GLP-1s (Regulatory): On February 6, 2026, the FDA announced a formal intent to restrict the use of active pharmaceutical ingredients (APIs) for non-approved compounded GLP-1 drugs, targeting "mass-marketed" alternatives from companies like Hims & Hers as the national supply of brand-name versions stabilized
Notably, even with Lilly only down less than 10% from its all-time high, Wall Street analysts continue to forecast substantial gains ahead
GLP-1 medications like liraglutide and semaglutide both work by mimicking the action of the glucagon-like peptide-1 hormone, which helps to reduce appetite and slow gastric emptying
Gulzar MM, Sarani ZA, Tariq M, Knerr I BMJ case reports 2025
Joe Rogans Diet: His return to a carnivore-based diet, what he eats day to day, and how it fits alongside his broader health and performance routine